Abstract
Cancer, once considered as an incurable disease, today, becomes not that difficult to be treated due to the newly emerging nanotechnology and the rapid development of “smart” drug delivery systems. New cancer therapeutics ought to overcome the defects of conventional drug delivery systems, such as nonspecific bio-distribution or targeting, short circulation time, etc. Tumor targeted drug delivery systems basically includes two strategies: passive and active targeting. Passive targeting is often referred to the enhanced permeability and retention effect (EPR effect) due to the enhanced vascular penetration of tumor capillaries and limited lymphatic drainage of lymphatic capillaries. Active targeting systems are based on local stimuli characteristic of the target pathological zone (such as, increased temperature or lowered pH values, redox potential changes, characteristic of inflamed, the receptor mediated internalization by target cells, etc.). Intriguingly, the combination of the two strategies above is promising and exciting. Herein, we give a brief review of tumor targeted drug delivery systems based on tumor cell itself and its external milieu.
Keywords: Drug delivery systems, smart nanocarriers, tumor targeting, Carcinoma, conventional therapeutics, blood circulation, ENDOCYTOSIS, NANOMEDICINES, PASSIVE TARGETING
Drug Delivery Letters
Title: “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems
Volume: 1 Issue: 1
Author(s): Zhigang Hu, Fei Huo, Yi Zhang, Chunyang Chen, Kehua Tu, Hongliang Jiang and Li-Qun Wang
Affiliation:
Keywords: Drug delivery systems, smart nanocarriers, tumor targeting, Carcinoma, conventional therapeutics, blood circulation, ENDOCYTOSIS, NANOMEDICINES, PASSIVE TARGETING
Abstract: Cancer, once considered as an incurable disease, today, becomes not that difficult to be treated due to the newly emerging nanotechnology and the rapid development of “smart” drug delivery systems. New cancer therapeutics ought to overcome the defects of conventional drug delivery systems, such as nonspecific bio-distribution or targeting, short circulation time, etc. Tumor targeted drug delivery systems basically includes two strategies: passive and active targeting. Passive targeting is often referred to the enhanced permeability and retention effect (EPR effect) due to the enhanced vascular penetration of tumor capillaries and limited lymphatic drainage of lymphatic capillaries. Active targeting systems are based on local stimuli characteristic of the target pathological zone (such as, increased temperature or lowered pH values, redox potential changes, characteristic of inflamed, the receptor mediated internalization by target cells, etc.). Intriguingly, the combination of the two strategies above is promising and exciting. Herein, we give a brief review of tumor targeted drug delivery systems based on tumor cell itself and its external milieu.
Export Options
About this article
Cite this article as:
Hu Zhigang, Huo Fei, Zhang Yi, Chen Chunyang, Tu Kehua, Jiang Hongliang and Wang Li-Qun, “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems, Drug Delivery Letters 2011; 1 (1) . https://dx.doi.org/10.2174/2210304x11101010067
DOI https://dx.doi.org/10.2174/2210304x11101010067 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy
Current Genomics Mitochondria as Therapeutic Targets of Estrogen Action in the Central Nervous System
Current Drug Targets - CNS & Neurological Disorders Phospholipase A2 Isoforms as Novel Targets for Prevention and Treatment of Inflammatory and Oncologic Diseases
Current Drug Targets Cannabinoid Receptors as Therapeutic Targets
Current Pharmaceutical Design Human Endometrial and Ovarian Cancer Cells: Histone Deacetylase Inhibitors Exhibit Antiproliferative Activity, Potently Induce Cell Cycle Arrest, and Stimulate Apoptosis
Current Medicinal Chemistry Targeted Drug Delivery System for Platinum-based Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Prolactin Protects Against the Methamphetamine-Induced Cerebral Vascular Toxicity
Current Neurovascular Research Nutritional Approaches to Modulate Oxidative Stress in Alzheimers Disease
Current Alzheimer Research Hunting for Peptide Substrates of Prolyl Oligopeptidase: Classical Versus Non-Classical Bioactive Peptides
CNS & Neurological Disorders - Drug Targets Glycogen Synthase Kinase-3 - An Overview of An Over-Achieving Protein Kinase
Current Drug Targets Hormonal Control of the Neuropeptide Y System
Current Protein & Peptide Science Disintegrins from Snake Venoms and their Applications in Cancer Research and Therapy
Current Protein & Peptide Science Mitochondrial Dysfunction and Oxidative Stress in Insulin Resistance
Current Pharmaceutical Design Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives
Current Medicinal Chemistry H2O2 Signalling Pathway: A Possible Bridge between Insulin Receptor and Mitochondria
Current Neuropharmacology Neuroinflammation and Neuroprotection: An Update on (Future) Neurotrophin-Related Strategies in Multiple Sclerosis Treatment
Current Medicinal Chemistry Multifunctional Role of Pacap-Like Peptides in Molluscs
Protein & Peptide Letters Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology From Bacteria to Antineoplastic: Epothilones A Successful History
Anti-Cancer Agents in Medicinal Chemistry